EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling

Jun Kim iD, Seounghun Kang

Pharmaceutics · 29.07.2026 · 18 (8) · 934

DOI: 10.3390/pharmaceutics18080934 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.07.2026. Verfasst von Jun Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Soongsil University, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies because of aggressive tumor biology, pervasive therapeutic resistance, rapid adaptive reprogramming, and a profoundly immunosuppressive tumor microenvironment. This review summarizes recent advances in KRAS-targeted therapies, DNA damage response (DDR)-directed strategies, immune-redirection platforms, and tumor microenvironment modulation.

Methods

We conducted a narrative review of peer-reviewed publications, clinical trial reports, trial registries, and selected conference data addressing emerging therapeutic strategies for PDAC.

Results

KRAS-targeted therapies, including KRAS G12D-selective and multi-selective RAS(ON) inhibitors, have demonstrated substantial preclinical and emerging clinical activity while revealing diverse mechanisms of adaptive resistance. DDR-directed approaches are expanding beyond BRCA-mutated disease toward functional homologous recombination deficiency, replication stress, and synthetic lethality. In parallel, bispecific antibodies, T-cell engagers, and CAR-T-cell therapies have generated preliminary evidence of antitumor activity, although stromal exclusion, antigen heterogeneity, and immune suppression remain major barriers. These advances indicate that therapeutic resistance in PDAC is a dynamic process involving interconnected oncogenic, genomic, stromal, metabolic, and immune mechanisms.

Conclusions

Future progress will require biologically informed treatment frameworks integrating complementary therapeutic modalities according to baseline tumor biology and treatment-induced adaptive states, supported by longitudinal biomarkers and rational clinical trial design.

Schlagwörter

Stichwörter der Autor:innen

DNA damage responseKRAS inhibitorimmune redirectionpancreatic ductal adenocarcinomaprecision oncologytumor microenvironment

Autor:innen und Institutionen

  • Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea.
  • AI-Bio Convergence Research Institute, Soongsil University, Seoul 06978, Republic of Korea.

ORCID-Profile: Jun Kim

Förderung

  • Soongsil University
  • Ministry of Education

Zitieren

APA

Kim, J., & Kang, S. (2026). Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling. Pharmaceutics, 18(8), 934. https://doi.org/10.3390/pharmaceutics18080934

Vancouver

Kim J, Kang S. Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling. Pharmaceutics. 2026;18(8):934. doi:10.3390/pharmaceutics18080934

BibTeX
@article{Kim2026,
  author = {Kim, Jun and Kang, Seounghun},
  title = {Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {934},
  doi = {10.3390/pharmaceutics18080934}
}
Kostenlos starten →